Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31716290 | 0.92 | AHR (0.40) | AHRGAATRPV4KHKCSNK2A1 | |
| SCHEMBL20517749 | 0.83 | TRPV4 (0.39) | AHRGAATRPV4KHKHTT | |
| SCHEMBL404475 | 0.82 | GAA (0.46) | AHRGAATRPV4KHKHTT | |
| SCHEMBL28863952 | 0.82 | POLB (0.38) | GAAKHKHTTABL1KDR | |
| SCHEMBL11689061 | 0.80 | HTT (0.36) | GAAKHKHTTABL1KDR | |
| SCHEMBL404910 | 0.79 | CD44 (0.58) | GAATRPV4KHKHTTCSNK1A1 | |
| SCHEMBL15407630 | 0.75 | GAA (0.44) | AHRGAATRPV4KHKHTT | |
| SCHEMBL12414780 | 0.75 | TSHR (0.41) | HTTCD44ABL1KDRMEN1 | |
| SCHEMBL22636768 | 0.75 | TRPV4 (0.39) | AHRGAATRPV4KHKHTT | |
| SCHEMBL20045535 | 0.75 | ALDH1A1 (0.36) | AHRTRPV4CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2739609-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2019-07-17 | — | — | EP | disclosed |
| EP-2739609-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2019-07-17 | — | — | EP | disclosed |
| US-20170128434-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2017-05-11 | — | — | US | disclosed |
| US-20170128434-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2017-05-11 | — | — | US | disclosed |
| US-20170128434-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2017-05-11 | — | — | US | disclosed |
| US-9586891-B2 | Estrogen receptor ligands | KARO PHARMA AB (SE) | 2017-03-07 | — | — | US | disclosed |
| US-9586891-B2 | Estrogen receptor ligands | KARO PHARMA AB (SE) | 2017-03-07 | — | — | US | disclosed |
| US-9586891-B2 | Estrogen receptor ligands | KARO PHARMA AB (SE) | 2017-03-07 | — | — | US | disclosed |
| US-20140323518-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323518-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323518-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2014-10-30 | — | — | US | disclosed |
| EP-2739609-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013017654-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2013-02-07 | — | — | WO | disclosed |
| WO-2013017654-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2013-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128434-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, GPER1 | AHR 1798/4885GAA 4304/4885TRPV4 1049/4885 |
| US-20140323518-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, GPER1 | AHR 1798/4885GAA 4304/4885TRPV4 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.